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Nearly 50 million people are aicted with epilepsy, worldwide. These patients suffer from
unprovoked seizures, where neurons in the cerebral cortex under go uncontrolled, hypersyn-
chronous firing of neurons. 30% of patients with epilepsy do not respond to drug treatments.
For these patients, surgical treatment involving the removal or disconnection of brain matter
is one of the only alternatives. Such surgical treatments often rely on long-term monitoring
of neuronal activity in the brain using subdurally implanted surface electrodes to locate the
epileptic focus, but these clinical methods for mapping neuronal activity suffer from low
spatial resolutions and poor noise, which can limit the success of surgical treatments where
an error of even 1 mm can be critical.
The work described here involves the development of an implantable system for per-
forming optical recordings of intrinsic signal (ORIS) on the surface of the brain. By taking
advantage of the unique absorption spectrum of hemoglobin, cerebral blood volume (CBV)
can be measured via reflectivity changes in the brain at at specific wavelengths of light. Due
to the metabolic demands of the brain, the exaggerated neuronal activity and spiking associ-
ated with epileptic seizures can be detected indirectly through changes in CBV. While high
resolution ORIS measurements have been recorded using externally mounted CCD sensors,
this work presents some of the first developments in producing a fully implantable ORIS
sensor.
Progress in the development of an implantable ORIS sensor described here includes:
an implantable organic light emitting diode (OLED) and organic photodetector (OPD)
integrated on a highly flexible parylene-c substrate, an implantable sensor using a microLED
array embedded on a flexible polyimide substrate, and the application of quantum dots to
microLEDs for optical down-conversion. Successful in vivo detection of seizures is achieved
with high signal-to-noise using these methods. Additionally, spatial localization of seizure
activity is performed using the microLED array. These developments represent crucial first
steps in the development of a full 2D neuronal mapping system using implantable ORIS
devices.
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Recent progress in flexible electronics and sensors have shown promise for enabling a new
class of wearable and implantable healthcare devices.[1, 2, 3, 4, 5, 6, 7, 8] By coupling
advanced hardware with novel computational methods to collect larger sets of data with
higher granularity than ever before,[9, 10, 11] it may be possible to greatly improve health-
care diagnostics and patient care, as well as our understanding of human physiology. One
application in particular that can greatly benefit from advances in clinical hardware sensors
is the diagnosis and treatment of epilepsy.
1.1 Epileptic Seizures
Epilepsy is a chronic neurological disorder which aicts nearly 50 million people worldwide.[12]
A patient is diagnosed with epilepsy when they have two or more unprovoked seizures that
are not the result of another medical condition such as fever or drug withdrawal. While
seizures can occur for a variety of reasons other than epilepsy, the causes for epilepsy itself
are not well understood, as each case of epilepsy has its own distinct history and response
to treatment.[13]
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Seizures typically manifest as an excessive, hypersynchronous firing of a population of
neurons in the cerebral cortex, the largest and most anterior section of the brain.[14] The
cerebral cortex is divided into left and right hemispheres that serve major sensory, motor,
and cognitive functions (Figure 1.1). There are three major categories of seizures: focal
seizures, generalized seizures, and unclassifiable seizures.[15] Focal seizures are those that
originate within a neuronal network that is limited to one cerebral hemisphere, whereas
generalized seizures involve networks in both cerebral hemispheres. [15, 14] Focal seizures
can evolve into generalized seizures if the seizure activity spreads from neuronal networks
in one hemisphere to both.[15] The external symptoms of a focal seizure that has evolved
into a generalized seizure are difficult to distinguish and are commonly only identified by
electroencephalography (EEG) study. Subcategories of generalized seizures can include those
of absent seizures where the patient experiences brief lapses of consciousness and atonic
seizures where a sudden loss of posture can occur. Unclassifiable seizures are those that
cannot yet be designated as either focal or generalized without further study.[15]
Figure 1.1: Diagram of the cerebral hemispheres.[16] Image courtesy of blausen.com
staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2).
DOI:10.15347/wjm/2014.010. ISSN 2002-4436. Reused under the Creative Commons At-
tribution 3.0 Unported license https://goo.gl/KfFFfo
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1.1.1 Seizure Propagation and Treatment
Focal seizures can typically initiate in localized regions of the cortex and propagate to
neighboring regions. According to Harrison's Principles of Internal Medicine, The ini-
tiation phase is characterized by two concurrent events in an aggregate of neurons: (1)
high-frequency bursts of action potentials and (2) hypersynchronization. The bursting ac-
tivity is caused by a relatively long-lasting depolarization of the neuronal membrane due
to influx of extracellular calcium (Ca2+), which leads to the opening of voltage-dependent
sodium (Na+) channels, influx of Na+, and generation of repetitive action potentials. This
is followed by a hyperpolarizing afterpotential mediated by γ-aminobutyric acid (GABA)
receptors or potassium (K+) channels, depending on the cell type.[15] With normal, healthy
neuronal activity, hyperpolarization and surrounding inhibitory neurons prevent the prop-
agation of the bursting activity; however, with sufficient activation by an increase of ion
concentrations, enhanced neurotransmitter release, excitation of amino acid receptors, or
stimulation of the neuronal tissue, neighboring neurons can be recruited for the propagation
of seizures to contiguous areas of the cortex or to distant areas via pathways such as the
corpus callosum.
The most common treatment method for epilepsy is through antiepileptic drug (AED)
therapy, with the primary goals of reducing the frequency or eliminating seizures to the
greatest extent possible, evading adverse side effects of long term treatment, and aiding
patients in maintaining normal social, vocational, and lifestyle function.[13] Typically, AED
therapy works by blocking the initiation or propagation of seizures.[15] The most common
drugs used for inhibiting epileptic seizures may achieve this by inhibiting Ca+ channels in
the neurons[13]or by increasing the presence of neurotransmitters that mediate synaptic
transmission, such as gamma aminobutyric acid (GABA).[13]
Unfortunately, approximately 30% of patients with epilepsy do not respond to anti-
epileptic drugs.[13, 14] For these patients, the unpredictability of seizures occurring dra-
matically impacts the quality of life for both patients and caregivers.[17] One of the only
alternative treatments for patients who are unresponsive to AED is epilepsy surgery which
removes or disconnects pathology sections of brain matter.
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Patients are eligible for resective epilepsy surgery if the areas of the brain responsi-
ble for seizures are safe to remove without overly severe levels of disruption to neurological
function.[14, 15] In order to maximize the success of surgery, patient selection is critical. Sur-
geons employ thorough diagnostic tests including video and EEG monitoring, neuroimaging,
and neuropsychometric studies. [14] Once a patient has been selected for surgery, extensive
chronic study by neural imaging is required to identify the pathology areas of the brain and
develop a surgical treatment plan. Thus, the development of high fidelity, high spatiotem-
poral resolution neural imaging capabilities are crucial for increasing the success of epilepsy
surgeries, as well as furthering the understanding of complicated neurological disorders like
epilepsy.
1.1.2 Mapping Neural Activity
Clinical practice currently measures neural activity via EEG and Electrocorticography (ECoG).
These techniques utilize a grid of surface electrodes which measure the electrical local field
potential of cortical neuronal dendrites near the brain's surface. The electrical signals are
conducted through the surface of the skull or cerebral cortex, for EEG and ECoG respec-
tively. When neuronal cells activate, the flow of ions through the synapse creates a dipole
outside the dendrite. The oscillation of electric field potential due to these dipoles can then
be detected by the surface electrodes used in EEG and ECoG. While an EEG electrode
placed on the scalp is unable to pick up single neuron activity, they are able to detect the
potential changes due to clusters of thousands of neurons firing synchronously. [14]
For surgical candidates, ECoG recorded with a subdurally implanted array of surface
electrodes covering a large surface of the brain is the standard of care for determining the
focus and propagation of seizures (Figure 1.2). Typical studies prior to surgery involve
long-term monitoring of neural activity with an implanted ECoG array lasting up to a few
weeks, in addition to acute studies involving short-term implantation coupled with neural
stimulation.[14, 15] While clinical ECoG measurements have improved resolution (typically
<1 cm and <1 ms) and signal-to-noise ratio (SNR) over EEG, a greater spatiotemporal
resolution and SNR of neural activity measurements would greatly aid treatment by surgical
resections where even small errors on the order of 1 mm can be significant.[18]
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Figure 1.2: Schematic diagram of ECoG measurement using a subdurally implanted array of
surface electrodes.[16] Standard clinical surface electrodes can perform chronic measurement
of neural activity, but have relatively low spacial resolutions (< 1 cm). Image courtesy
of: Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of
Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. Reused under the Creative
Commons Attribution 3.0 Unported (CC BY 3.0) license https://goo.gl/KfFFfo
1.2 High Resolution Imaging
Standard clinical methods for high resolution imaging include magnetic resonance imaging
(MRI), positron emission tomography (PET), single photon emission computed tomography
(SPECT), and magnetoencephalography (MEG), and functional MRI (fMRI). [14] While
these techniques can produce maps of neural imaging with high spatial resolutions (< 1mm)
and are valuable for acute studies, these methods are not ideal for chronic studies as pa-
tient movement is restricted and functional dyes are required for some of the mentioned
techniques.
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Research in the field of advanced ECoG has sought to improve the resolution and fi-
delity of subdurally implanted surface electrode arrays with advances in both the sensing
hardware[19, 20, 21] and computational analysis[9] involved. For instance, recent work by
Khodagholy et al. has introduced a flexible, organic electronics-based array with interelec-
trode spacing as small as 23 µm.[20, 21] These advances coincide with recent progress in the
field of wearable and implantable flexible electronic sensors which holds much promise for
future advanced and personalized healthcare diagnostics. [22, 1, 6, 23, 7, 8, 24, 4]
1.3 Optical Recording of Intrinsic Signal (ORIS)
A promising alternative to ECoG imaging of neural activity is the optical recording of in-
trinsic signal (ORIS). ORIS monitors changes in optical signals associated with neuronal
activity.[25] By monitoring optical reflectivity changes caused by cerebral blood volume
(CBV) and cerebral blood flow (CBF), seizure events in the brain have been recorded with
high spatiotemporal resolution (<200 µm and <200 ms). [26, 27, 28, 29] By taking advan-
tage of the absorbance spectra of oxygenated and deoxygenated hemoglobin (Figure 1.3),[30]
total CBV can be recorded by measuring the reflectivity of light at the isosbestic, or equal
absorption, wavelengths for hemoglobin. Since, the brain is tightly vasoregulated, seizure
events which induce exaggerated neuronal activity in localized regions of the brain are cor-
related with drastic changes in CBV and CBF that can be precisely mapped using ORIS.
Work by Suh et. al demonstrated 2D mapping of seizure activity with spatial resolutions
below 200 µm using a suspended CCD camera to capture reflected ORIS signals.[29]
While ORIS can provide high spatiotemporal resolution imaging of seizure activity with-
out the need for harmful dyes, an ORIS measurement system for clinical and long-term
monitoring of neuronal activity has not been demonstrated. ORIS measurements using a
suspended camera require the patient to be stationary, with their brain exposed. Early
work in developing an implantable measurement system includes an ORIS sensor that uses
off-the-shelf light emitting diodes and photodetectors integrated on a flexible substrate.[31]
This semi-flexible device is able to perform seizure detection by ORIS with high signal-to-
noise ratio (SNR), but is limited by the large dimensions of the components used. These
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Figure 1.3: Hemoglobin absorbance spectra. Measuring reflectivity of light at isosbestic
wavelengths where oxygenated and deoxygenated hemoglobin absorb light equally gives a
relative measure of total CBV. The devices in this work target the isosbestic points at 449
nm, 522 nm, and 548 nm. Absorbance data provided by Prahl, et al.[30]
constraints limit the practicality of the device for comfortable subcranial implant, as well as
the density of imaging elements needed to achieve high spatial resolutions.
1.4 Objectives and Approach
The objective of the work presented here is to advance the development of a subcranially
implantable ORIS sensor for performing acute and chronic measurement of neuronal activity.
An implantable ORIS sensor has the benefit of being practical for clinical applications, in
addition to having improved seizure detection capabilities due to the active optical elements
being in closer proximity to the surface of the brain. The requirements of such a device
include: a soft and flexible biocompatible substrate for comfortable and safe implantation,
a bright emitter for providing light input, a responsive photodetector for capturing subtle
changes in optical reflectivity, and long operating lifetimes. In order to achieve device
performance that meets these criteria, several novel display technologies have been adopted
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for use in ORIS sensing. Two main device architectures presented here are: 1) an optical
sensor based on flexible organic light emitting diodes and organic photodiodes 2) an optical
sensor that utilizes microLEDs embedded on a flexible polyimide substrate with modification
via quantum dot optical down-conversion.
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Chapter 2
Basics of Flexible Optoelectronics
2.1 Introduction
This chapter reviews the basic operating principles of various flexible electronic and opto-
electronic technologies used in this work. The primary elements involved in the development
of an implantable ORIS sensor are a stable, bright emitter in the form of a light emitting
diode (LED) and a photosensitive detector. While the use of flexible LEDs has been exten-
sively studied for display and communication applications, the adoption of these devices for
biomedical sensing is relatively new. A schematic showing the basic operating principles of
an implantable ORIS sensor is shown in Figure 2.1.
2.2 LEDs and Photodiodes
Standard p-n junction diodes involve doped p-type semiconductor, where holes are the ma-
jority mobile charge carrier, abutted against an n-type material, where electrons are the
majority mobile charge carrier. At zero bias, a depletion region of space charge forms on
either side of the p-n interface due to charge diffusion. In the steady state, the electro-
static fields from the space charge in the depletion region prevent further diffusion of charge
across the junction. In reverse bias, the depletion region is widened and practically no cur-
rent flows, except at extreme voltages where device breakdown occurs. Under forward bias,









Figure 2.1: Schematic showing the design and operation of an implantable ORIS sensor.
The primary elements include an LED and a photodetector integrated on a thin, highly
flexible substrate.
is able to diffuse across the junction at bias voltages above the threshold. Thus, current is
restricted to flow in one direction across the diode.
LEDs operate similarly to standard p-n junction diodes, except that the recombination
that occurs at the interface between the n-type semiconductor and p-type semiconductor
under forward bias is radiative, resulting in the generation of photons (Figure 2.2). Since
LEDs are fabricated from mostly transparent materials, the light produced by recombination
at the interface, can escape. LEDs conventionally are made from direct band gap materials
like GaAs or GaN, which have higher probabilities of radiative recombination than indirect
band gap materials. The wavelength of light emitted by an LED is determined by the
bandgap of the emissive material where recombination occurs.
Photodiodes generally operate in reverse of LEDs. Light incident on the photosensi-
tive material generates charge separation which is collected by the anode and cathode of
the device. LEDs can operate like photodiodes, according to the Mims effect,[32, 33] but
have larger bandgaps which diminishes the available range of wavelengths for producing
photocurrent. Photodiodes can be operated in photovoltaic mode (no electrical bias) or
10
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Figure 2.2: Schematic diagram of an LED. Radiative recombination in the p-n junction
results in light emission at photon energies equal to the bandgap.
photocurrent mode (under a reverse bias). Photocurrent mode can increase the response
time of the detector, but may introduce more electrical noise.
Conventional LEDs and photodiodes are typically very rigid due to the crystalline semi-
conductor materials they are made of, as well as the typical glass and sapphire substrates
that are used for such devices. Silicon and other crystalline materials can be made flexi-
ble by using techniques such as wafer thinning and fabrication of silicon nanoribbons,[34,
35] but high performance devices are challenging to fabricate and are not intrinsically
biocompatible.Hematoxylin- and eosin-stained histological
e-
+
Figure 2.3: Schematic diagram of a photodiode. Incident light on the photodiode creates
charge separation due to the photoelectric effect. The charges are swept towards the contacts
due to the intrinsic electric field, generating a photocurrent.
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2.3 Organic Semiconductors
One method of producing flexible electronics devices is to utilize organic semiconducting
materials. Organic semiconductors are comprised of organic (containing carbon) small
molecules or polymers and have the advantage of being intrinsically flexible, partly due
to the thin nature of most organic electronic devices, with the total thickness of the active
materials typically under 1 µm ). Due to the fact that bonds between organic molecules tend
to be weak, often formed by van der Waals interactions, thermal budgeting for processing
and fabricating thin film organic semiconductors is low.[36] Therefore, organic semiconduc-
tor devices can be fabricated on almost any substrate, including plastics that cannot handle
the intense thermal processing needed for many inorganic crystalline semiconductors. Or-
ganic semiconductors can even be fabricated by solution processing, an area of great interest
for applications such as roll-to-roll processing and large area fabrication.[36]
Charge transport in organic semiconductors typically occurs via chains or sheets of sp2-
hybridized carbon. The electronic configurations of carbon atoms in organic semiconductors
often form hybrid sp molecular orbitals which collectively have a lower energy than if the
carbon molecules remained in their neutral valence electron configuration (2s2, 2p2). Shared
sp2 orbitals in carbon-carbon bonds form what are known as σ-bonds which are strong and
highly directional.[36] Perpendicular to the axis of the σ-bonds, electrons in the weakly
associated pz, or pi, orbitals of the hybridized carbon form what are known as conjugated
pi-bonds. These delocalized pi-electrons can organize into multiple electronic configurations
for a single type of molecule; an example of this is napthalene whose conjugated bonds are
depicted as alternating single and double bonds in Figure 2.4. These delocalized charge
carriers in the pi-bonds allow for charge transport in organic semiconductors.
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Figure 2.4: The resonance forms of napthalene. The alternating double and single bonds
form conjugate pairs, with the extra electrons forming the double bonds not having a specific
localized orientation. This charge conjugation is the mechanism which gives rise to charge
transport and semiconducting properties of organic semiconductors.
Charge transport in disordered organic materials is often described by hopping mecha-
nisms, where the carrier lifetimes are short, resulting in charge mobilities which are typically
smaller than inorganic crystalline semiconductors.[36] Also, unlike inorganic semiconductors
which can transport both positive and negative charge carriers, many organic materials only
support charge transport for one kind of charge carrier. Rather than n-type and p-type
material designations which refer to doping in inorganic semiconductors, different types of
organic semiconductors are referred to as hole transport (HTL), hole injection (HIL), hole
blocking (HBL), electron transport (ETL), electron injection (EIL), and electron blocking
(EBL) layers based on their charge transport characteristics. In OLEDs, the layer where
radiative recombination occurs is also called the emissive layer (EML).
For organic molecules, a network of these conjugated molecular orbitals form, some of
which may or may not be filled depending on the energy state of the molecule. Analogous to
the conduction band of inorganic semiconductors, electrons are transported along the lowest
unoccupied molecular orbital (LUMO). Holes are transported along the highest occupied
molecular orbital (HOMO), similar to the valence band of inorganic semiconductors. The
energy gap, Eg, between HOMO and LUMO is analogous to the band gap of inorganic
semiconductors and is generally related to the conjugation length of the organic molecule












Figure 2.5: Example of the band structure of an OLED. Recombination in the EML results
in green light emission whose wavelength is determined by the HOMO-LUMO gap of AlQ3.
2.3.1 Organic LED (OLED)
OLEDs are formed using electroluminescent organic semiconductor materials. OLEDs are
commonly produced by stacking thin films of organic semiconducting material to form
a heterojunction structure similar to a p-n junction. An example of the band diagram
for an OLED heterojunction is shown in Figure 2.5.[37] The device stack is as follows:
indium tin oxide (ITO) is used as a transparent anode, n,n´-bis(3-methylphenyl)-n,n´-
diphenylbenzidine (TPD) forms the HTL, tris(8-hydroxyquinolinato)aluminium (AlQ3) forms
the EML/ETL, and aluminum forms a reflective cathode.
Efficiency
The efficiency of an OLED is a measure of a device's ability to convert electrical energy into
light. The internal quantum efficiency refers to the ratio between charge converted into light
due to recombination and the total number of injected charge during forward bias. Internal
quantum efficiency can be calculated as:
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ηint = γζsq
γ is the charge carrier balance. ζs is the exciton generation efficency, i.e. the efficiency
for exciting charge carriers into singlet (for fluorescence and phosphorescence) and triplet
(for phosphorescence only) excited states. q is the fluorescence quantum efficiency, or the
efficiency of generating photons from excited singlet or triplet states depending on whether
the OLED is fluorescent or phosphorescent.[38]
Singlet and triplet states refers to the excited charge states that occur according to the
pauli exclusion principle, where no two electrons occupying the same orbital can have the
same magnetic spin state. In the ground state, two electrons occupying the same orbital
must have opposite spins from each other. This configuration is called the singlet ground
state (Figure 2.6). When light is absorbed by one of the electrons, they are excited to an
orbital with higher energy. If the spin state of the excited electron is preserved during the
transition, it is in a singlet excited state. If the spin state has been reversed and the spins of
both the unexcited electron and the excited electron are now aligned in parallel, it is called a
triplet state. Singlet-to-triplet and triplet-to-singlet transitions are typically far less likely to
occur due to the need for a spin transition on top of the usual energy absorption. Fluorescent
OLEDs are only able to produce light emission by singlet to singlet-state-transitions. Excited
singlet states can relax to triplet excited states by intersystem crossing, but these transitions
tend to have longer relaxation times and don't result in radiative emission for fluorescent
OLEDs. Thus, the theoretical maximum efficiency for a fluorescent OLED is 25% since light
emission only occurs via 1 out of 4 available excited states (1 singlet excited state and 3
triplet excited states).[38] Phosphorescent OLEDs tend to include heavy metal structures
which allow for photon emission by both triplet-to-singlet relaxation and singlet-to-singlet
relaxation. Therefore, phosphorescent OLEDs have a theoretical maximum efficiency of
100%.[38, 39, 40]
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Figure 2.6: Diagram of singlet and triplet excited states.
External quantum efficiency (EQE) is the efficiency of converting injected charge into
photons that can be extracted as light emission and provides a more useful metric for device
performance. In addition to the same factors involved with internal quantum efficiency, EQE
also takes into account the ability of the device to outcouple light. EQE can be calculated
with the following equation:
ηext ∼= ηoγζsq
, where ηo is the outcoupling efficiency of the device. Outcoupling efficiency can be affected
by the choice of substrate, device thickness, device geometry, among many other factors.
One method, among many, of improving outcoupling effciency is by integrating a microlens
into the device or substrate in order to improve light extraction and enhance directionality
of the emitted light.[41, 42]
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Pathways of Degradation
A chief concern with the use of OLEDs is the relatively short operational lifetimes. The
organic materials and electrodes used are vulnerable to oxidation and moisture-related degra-
dation when exposed to atmospheric conditions. For this reason, OLEDs are typically fab-
ricated and assembled in inert environments, such as nitrogen or argon filled gloveboxes.
Lifetime of OLED devices are usually quantified by measuring the luminance over time,
during constant operation. One standard metric for the lifetime is the luminance half-life,
or the time it takes for an OLED's luminance to decay to half of its initial value.
Environmentally caused degradation to the device often manifests in dark spots,[43]
which decrease their luminance. Dark spot generation can be caused by local oxidation
of the cathodes, microscopic shorting between the electrodes due to localized heating and
morphological defects, charge accumulation at layer interfaces, and other structural defects
or damage.[44, 45, 38, 46] Lifetime can be improved by simply improving the efficiency of the
device, reducing the thermal and electrical stress placed on the OLED.[46, 43] Furthermore,
environmental factors on device lifetime can be mitigated by using encapsulation or hermetic
sealing, providing a barrier against harmful oxygen and moisture.[44, 47] For flexible OLED
applications, flexible encapsulation schemes can also involve alternating stacks of deposited
thin barrier films.[48, 49, 50]
2.3.2 Organic Photodetector (OPD)
Organic photodiodes (OPDs) and organic solar cells operate similarly to their silicon coun-
terparts. Instead of n-type and p-type semiconductors, the photosensitive materials that
form the junction in OPDs are called electron acceptors and electron donors. When light
is absorbed by charge carriers in organic materials, an exciton (bound electron-hole pair)
with binding energy, Ebinding, is formed, rather than free charge carriers as with inorganic
photodetectors.[51] In order to generate photocurrent, the exciton binding energy must be
overcome to convert the exciton into free charge, and monolayers of organic photosensitive













Figure 2.7: Photoexcitation and free charge conversion in a donor-acceptor junction.
One strategy of overcoming Ebinding, is to create an electron donor/electron acceptor
interface where charge transfer can occur after photoexcitation.[51] Electrons excited in the
donor can transfer into the acceptor if the difference between the donor and acceptor LUMO
levels (or electron affinities) is greater than EbindingD , the exciton binding energy for the
donor. Similarly the photogenerated holes in the acceptor can transfer into the donor if the
difference between the donor and acceptor HOMO levels (or ionization potentials) is greater
than EbindingA , the exciton binding energy for the acceptor. To achieve high photoinduced
charge separation yields, the photogeneration of excitons must occur within a diffusion length
of the donor-acceptor interface.[53] One approach to maximizing the efficiency of OPDs is
to create a bulk heterojunction device which has a blended donor-acceptor layer across the
majority of the device.[54, 55]
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Responsivity and Efficiency
The internal quantum efficiency of the OPD device is the ratio of charge carriers collected
at the contacts to the number of absorbed photons, whereas the external quantum efficiency
(EQE) is the ratio of charge carriers collected at the contacts to the total number of incident
photons on the OPD's active area. EQE is mainly determined by the efficiencies of the
free charge generation and the absorption cross section of the device. Responsivity, or the
extracted photocurrent divided by the incident light power, is related to EQE by :
R = EQE ∗ λq
hc
, where λ is the wavelength of incident light, c is the speed of light, h is planck's constant,
and q is the electron charge. Responsivity is the primary metric for determining the practical
effectiveness of an OPD for implantable ORIS sensors.
2.3.3 Fabrication Methods
OLEDs and OPDs are typically fabricated by either physical vapor deposition under high
vacuum or by solution processing. While solution processing is appealing for applications like
roll-to-roll processing and large area fabrication, it is typically more challenging than vacuum
deposition since many organic materials are sensitive to solvents and high temperatures,
and vacuum deposited OLEDs have traditionally had higher performance.[56] With those
considerations, OLED and OPD stacks deposited by thermal evaporation under high vacuum
tend to be patterned by shadow masking. With shadow masking, a hard stencil is used
to cover areas where deposition of the evaporated material in question is not desired. One
downside of vacuum deposition of organic device layers is the relatively long processing times
related to placing the devices in high vacuum for deposition and frequent mask exchange
for sophisticated heterojunctions.
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2.3.4 Biomedical Applications for OLED and OPD
Examples of OLED and OPD technology used in biomedical applications follows. These ex-
amples use a variety of fabrication methods and detection schemes, displaying the versatility
of OLED and OPD technologies applied to biosensors.
Organic Pulse Oximeter
Pulse oximetry is a noninvasive technique for optically measuring pulse and oxygenation
of blood through the skin. Typically, an emitter and photodetector pair are attached to a
body part, such as a fingertip or earlobe. Light at two wavelengths is transmitted through
the body part and changes in light absorbance are recorded by the photodetector. Changes
in the absorbance of the two wavelengths correspond to changes in oxygenated and deoxy-
genated hemoglobin, providing a measure of the current ratio of the two. An alternative
technique measures changes in reflected light from the surface of the body to achieve the
same diagnostic measurement.
An organic-based pulse oximeter was demonstrated by Lochner, et al. which replaced the
inorganic LED and photodetector elements with flexible OLEDs and OPDs. [57] The OLEDs
and OPD were fabricated using solution processing on a ITO-patterned glass substrate and
a polyethylene naphthalate (PEN) substrate, respectively, which could be wrapped around
a finger for performing transmissive pulse oximetry measurements. To fabricate this device,
electrodes for the OLEDs and OPDs were formed by vacuum deposition. The active organic
layers for the OLEDs were spin-coated, including a TFB:F8BT:TBT emissive layer for the
red OLED and a TFB:F8BT emissive layer for the green OLED. The active layers for the
OPD were blade coated, including a PTB7:PC71BM photosensitive layer. A schematic of the
completed device and extracted pulse and oxygenation measurements are shown in Figure
2.8.
The solution processing techniques used to fabricate the device shows the potential for
low cost, large area production of organics based wearable biosensors. Additionally, the
ability to fabricate onto flexible substrates enables applications requiring the placement of
the sensors on different areas of the body.
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Figure 2.8: a) Organic pulse oximeter replaces inorganic optoelectronic elements with
OLEDs and OPDs (b) Hardware block diagram for the system including amplification and a
microcontroller for data acquisition (c,d) Simultaneous oximetry measurements with a com-
mercially available inorganic oximeter probe and the organic oximeter probe, respectively.
Heart rate is determined from the timing of the systolic peaks in the oximetry signals. The
ratio of transmitted light at two wavelengths was used to calculate blood oxygen satura-
tion using BeerLambert's law. [57] Reprinted by permission from Lochner, Claire M., et




Laboratory-on-a-chip (LOC) technologies which integrate sensors and devices onto an inte-
grated circuit (IC) capable of performing complete laboratory measurements and functions
are a potential solution for providing next generation point-of-care diagnostics requiring a
compact physical footprint, portability, and ease of operation/automation. Wojciechowski,
et al. demonstrated a microfluidic LOC biosensor with an integrated OPD for performing
chemiluminescence (CL) detection of a toxin, Staphylococcal enterotoxin B (SEB). [58] CL
detectors record light emissions from chemical reactions that lead to photoexcitation and
are used for immunoassays and nucleic acid detection. [59] These detectors do not require
a light source as only a photodetector is needed to measure the photoemission from the
chemical reactions, decreasing the footprint and complexity of the devices.
Figure 2.9: Miniaturized biosensor using OPDs. [58] a) A glass slide with a printed OPD
sensor is used for CL detection of SEB b) The glass slide is placed into a portable con-
troller for data acquisition. Reprinted with permission from Wojciechowski, Jason R., et
al. "Organic photodiodes for biosensor miniaturization." Analytical chemistry 81.9 (2009):
3455-3461. Copyright 2009 American Chemical Society."
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The OPD based CL detector, shown in Figure 2.9, consisted of an OPD printed onto a
glass slide with an active area of 4 x 4 mm and a quantum efficiency of 50-60% at the 532 nm
wavelength. A sandwich immunoassay was performed directly onto the OPD slide, where
the slide was coated with α-SEB capture antibody, then exposed to SEB, and incubated
with horseradish peroxidase (HRP)-conjugated α-SEB tracer antibody (α-SEB-HRP) . An
opaque microfluidic chamber was attached to the sensor, and the slide was placed into a
portable OPD controller for data acquisition.
A representative measurement curve is shown in Figure 2.10. A SEB treated substrate
was added ~20 s into the recording, after which a detectable signal ~300 pA above the
baseline of ~80 pA was observed. A low limit of detection, enabled by the low dark current
of the OPD, for measuring SEB concentration of this device was stated at 0.5 ng/mL. This
limit of detection was comparable to CCD and PMT based detectors, demonstrating the
ability to produce compact, high performance biosensors using OPDs. [59]
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Figure 2.10: CL detection of SEB using an OPD. [58] Substrates treated with α-SEB, SEB,
and α-SEB-HRP were added ~20 s into recording. The concentration of SEB detected
measured in this plot was 5 ng/mL. Reprinted with permission from Wojciechowski, Jason
R., et al. "Organic photodiodes for biosensor miniaturization." Analytical chemistry 81.9
(2009): 3455-3461. Copyright 2009 American Chemical Society."
2.4 MicroLED
MicroLEDs are essentially inorganic LEDs, typically using nitride materials, that have been
miniaturized. MicroLEDs can be fabricated monolithically into arrays, or they can be fabri-
cated and released for pick and placement as individual elements in large arrays. The ability
to individually control and address LED elements reaching dimensions under 100 µm has
led to commercial interest in MicroLEDs for use in emissive displays, since they tend to
have superior performance over OLEDs in terms of operating efficiency and lifetime. Recent
advances in fabrication and processing of microLEDs has led to the availability of devices
with high brightness, even at relatively low bias voltages.[60, 61, 62] Also unlike OLEDs
which have relatively short operational lifetimes due to the degradation of the organic thin
films used, operational lifetimes for microLEDs are very long in comparison due to their
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inorganic composition. While these advantages in performance are ideal for use in long-
term in vivo measurement of ORIS, the drawback of microLEDs is their intrinsic rigidity.
Embedding microLEDs in a flexible circuit or substrate ultimately limits the flexibility of
the final device. Additionally, the planar geometry of most microLED elements can lead to
structurally vulnerabilities when used in a flexible device architecture; however, this can be
overcome with appropriate strain engineering. [63]
Work by Hong, et al. demonstrated a highly flexible display utilizing microLEDs as-
sembled on printed rigid islands composed of poly (methyl methacrylate) (PMMA). [63]
Printed rigit islands (PRIs) were embedded in PDMS forming a highly stretchable, soft
substrate with a thickness of ~50 µm. Patterned electrode traces were then inkjet-printed
onto the substrate, and microLEDs were soldered onto the PRIs. With this design, locally
strain-free among the soft substrate existed where the microLEDs were attached, preventing
detachment of the relatively flat and rigid microLED components from the flexible substrate.
Completed devices are shown in Figure 2.11. The strain engineered design for these flexible
microLED arrays provides a template for producing customized microLED arrays on highly
flexible substrates. This method provides a robust technique for building a resilient substrate
compatible with a wide variety of different microLED and other small, rigid optoelectronic
components. Such properties are vital for creating optoelectronic sensors and implantable
devices for biomedical applications.
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Figure 2.11: Strain engineered flexible microLED display. [63] Reprinted by permission from
Byun, Junghwan, et al. "Fully printable, strain-engineered electronic wrap for customizable
soft electronics." Scientific Reports 7 (2017): 45328.
MicroLEDs have found recent success in many fields of biomedical research. Some ap-
plications include: optogenetic stimulation,[64, 65] cochlear implant,[66], and biological flu-
orescence imaging.[67] . These demonstrations highlight the potential for microLED use in
biomedical sensors, including wearable and implantable electronics.
Optogenetics, where light is used to control the stimulation or suppression of neuronal
activity, represents a possible next generation treatment for neurological diseases such as
epilepsy and Parkinson's disease. [68] Typically, genetic modification is used to introduce
light sensitive proteins which drive specific, controlled actions in neurons with high tem-
poral resolution. For optogenetic applications involving neuronal cells inside of the body
or brain, MicroLEDs and microLED implants show great promise for implementing clinical
optogenetic treatments requiring efficient light input in a compact package.
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One successful application of microLEDs in this field was accomplished by Montgomery,
et. al where a microLED implanted on the surface of a mouse's brain was operated com-
pletely wirelessly for optogenetic stimulation. [65] In this work, a commercial blue microLED
was attached to a circuit for wireless power delivery. A mouse expressing channelrhodopsin
2 (ChR2) was implanted with the device and placed above a resonant cavity for RF wireless
power delivery (Figure 2.12). When the microLED was powered on, the blue light emission
activates ChR2 , triggering a circling behavior in the mouse's movement. The setup was
able to produce enough light input (1-20 mW/mm2) for ChR2 activation without exces-
sive heating of the animal (< 1 C change in body temperature) by duty cycling under 40%.
This achievement represents one practical approach to advanced healthcare for patients with
neurological diseases utilizing implantable optoelectronic devices.
MicroLEDs used for ORIS measurements in this work are commercially available and
are packaged as individual elements. The microLEDs have preformed AuSn solder bumps
for eutectic die attach. This allows the chips to be placed on a substrate or circuit with
a die bonder or via flip chip bonding, without the need for wire bonding or traditional
soldering. Because of the thermal processing required to reflow the AuSn solder, substrates
and materials that can withstand relatively high temperatures must be used. Additionally,
the small footprint of the bond pads calls for the use of photolithographically patterned
circuitry and bond sites, meaning the substrates used must be resistant to solvents and UV
light exposure. This limits the available substrates and materials for use in flexible and
implantable devices integdvanced healthcare for patients with neurological diseases utilizing
implantablerated with microLEDs.
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Figure 2.12: Wireless optogenetic stimulation of mice using a microLED implant a) A mouse
implanted with the wireless blue microLED implant was confined to an enclosure containing
a resonant cavity for wireless power delivery. The blue microLED was powered on wirelessly,
triggering a circulatory motor behavior induced by the activation of ChR2 b) Schematic of
the wireless microLED implant c) Photograph of the microLED implant [65] Reprinted by
permission fromMontgomery, Kate L., et al. "Wirelessly powered, fully internal optogenetics
for brain, spinal and peripheral circuits in mice." Nature methods 12.10 (2015): 969-974.
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2.5 Colloidal Quantum Dots
Colloidal quantum dots (QDs) are nanocrystals of semiconducting material produced by
solution processing that exhibit quantum effects due to their small size. The optoelectronic
properties of QDs are a function of their size and structure.[69, 70] Electrons in QDs be-
have much like particles in a box with quantum confinement effects in 3 dimensions.[70]
The discrete electronic states that arise from confinement result in very sharp spectral qual-
ities. As such, QDs have been adopted in many commercial displays and are being thor-
oughly researched for their potential applications in optoelectronnics [71, 72, 73] and imaging
biomarkers[74, 75, 76]. In particular the wavelength of emitted light can be tightly tuned
with narrow spectra by adjusting their size and structure, but without changing the mate-
rial composition.[73] This is a huge advantage over other optoelectronic devices which tend
to have less tunable emission spectra heavily dependent on the material composition. The
synthesis of QDs is discussed in the appendix.
2.5.1 Electroluminescent QDLEDs vs. Photoluminescent QDs
There are two variants of LED technology that takes advantage of QDs. The first is the
electroluminescent quantum dot LED (QDLED), which operates similarly to an OLED.
QDLEDs are comprised of a thin layer, often just a single monolayer, of QDs sandwiched
between charge transport layers. Excitons in QDLED can occur by either photon charge
injection, energy transfer, or by ionization of QDs.[73] The relaxation of these QD excitons
results in electroluminescence at photon energies equal to the bandgap of the QD. The
primary difference between different kinds of QDLEDs reside in the charge transport layers,
which may be formed with organic, inorganic, or a hybrid mixture of organic and inorganic
materials.[73, 71, 72]
Photoluminescent QDs differ from QDLEDs in that they are optically driven, rather
than electronically driven. This is most commonly seen in displays where white or blue
backlight is converted by a QD dye by absorption and re-emission.[77] Adopting QDs into
other optoelectronic devices can enhance them by providing a level of wavelength tunability
that is not normally available. This versatility is crucial in optimizing the performance of
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implantable and wearable optoelectronic sensors and expanding their practical applications.
2.5.2 Biomedical Applications for Quantum Dots
Examples of the use of QDs in biomedical applications follows. These examples take ad-
vantage of the unique optical properties of QDs for providing highly tunable narrowband
light emission. The progress reported in these examples show the promise of future clinical
therapies which utilize advanced materials such as QDs.
Photodynamic Therapy
Photodynamic therapies involve activating photosensitizers with specific wavelengths of light
to destroy cancer cells, for example via reactive oxygen species (ROS). [78] Therapies in-
volving external illumination for targeting cancer cells within the body are limited by the
penetration depth of the light and may have undesired side effects due to photosensitivity of
the skin. The use of nanotechnology to reduce or eliminate the required external irradiation
has been a topic of interest in the development of photodynamic therapies.
Work by Hsu et al. demonstrated the use of QDs in targeted photodynamic therapy re-
quiring zero external irradiation (Figure 2.13). [79] The QD-conjugate used in this work were
composed of light-emitting Renilla luciferase 8 (RLuc8) proteins and carboxylate-containing
QDs, which self illuminate via bioluminescent resonant energy transfer (BRET).[80] In the
BRET process, energy is released from the RLuc8 substrate coelenterazine, electronically
exciting the QD which than emit light. BRET was used to internally illuminate meta-tetra-
hydroxyphenyl-chlorin (m-THPC) photosensitizers in photodynamic therapy targeting the
reduction of tumors (Figure 2.13).
30
Figure 2.13: Schematic diagram of QDs used in targeted photodynamic therapy for tumor
suppression. [79] Reprinted from Biomaterials 34.4, Hsu, Chia-Yen, et al., "Bioluminescence
resonance energy transfer using luciferase-immobilized quantum dots for self-illuminated
photodynamic therapy.", Pages 1204-1212, Copyright 2013, with permission from Elsevier.
The successful reduction of tumor volume by BRET-induced photodynamic therapy is
shown in Figure 2.14. Mice were injected with different permutations of the QD-conjugate
(QD-RLuc8), photosensitizer loaded micelles photosensitizer (m-F), and coelenterazine and
then monitored for their tumor growth rates. For mice which received BRET-induced pho-
todynamic therapy (having received the full QD-RLuc8/m-F/coelenterazine treatment), sig-
nificant reduction of tumor volume was observed. This demonstrates the ability to use QDs
for the internal activation of photosensitizers in photodynamic therapies . This kind of
achievement may lead to effective clinical application of photodynamic therapies that uti-
lize QDs without the need for external light sources and can extend to applications beyond
photosensitizers that target cancer cells.
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Figure 2.14: Tumor suppression via QD-enabled targeted photodynamic therapy.[79] a)
Tumor volume was tracked for the different permutations of treatments. Mice which re-
ceived the BRET-induced photodynamic therapy showed a reduction in tumor volume b)
Stained sections of tumors c) Microscope image of tumors. Reprinted from Biomaterials
34.4, Hsu, Chia-Yen, et al., "Bioluminescence resonance energy transfer using luciferase-
immobilized quantum dots for self-illuminated photodynamic therapy.", Pages 1204-1212,
Copyright 2013, with permission from Elsevier.
32
QDLEDs for Photobiomodulation
The use of electroluminescent (EL) QDLEDs in wearable devices and biomedical devices
has gathered interest as QD technology has progressed both commercially and for research
purposes. Chen et al. demonstrated the use of EL QDLEDs for photobiomodulation, in
which light is used to stimulate cellular function. [81] Such treatments could potentially
aid with wound recovery via applications such as light emitting bandages. In their work,
QDLEDs which have brighter emissions at the necessary wavelengths (in the deep red region)
were proposed as an alternative to OLEDs which have struggled to meet the performance
requirements for such applications. The performance and structure of such QDLEDs is
shown in Figure 2.15.
These highly efficient QDLEDs produced high brightness emission, up to 165,000 Cd/m2
at a peak emission wavelength of 620 nm.[81] In-vitro studies of these QDLEDs used in
photobiomodulation therapy were performed using cell lines (HEp-2 [ATCC-CCL-2]; L929
[ATCC-CCL-1], 3T3 [ATCC-CRC-2593]) which act as surrogates for whole animal studies
of wound healing. The QDLEDs were placed underneath cell culture wells containing the
cell lines, and the QDLEDs were powered on for 10 min, illuminating the cell lines for
photobiomodulation therapy (Figure 2.16). Assay results at 24 hours post treatment showed
increased cell metabolism comparable to previous results achieved with inorganic LEDs
(up to 27.9% increase for the HEp-2 cell line). [81] While improvements in performance
for flexible QDLEDs of this type must be made in order to enable applications such as
wearable or bandage based photobiomodulation treatments, the devices demonstrated in
this work show the potential for utilizing the unique optical properties of QDs in wearable
and implantable applications.
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Figure 2.15: QDLED structure and performance. [81] a) Inverted QDLED structure b)
Emission spectrum of the EL QDLED. Insets show the structure of the QD and a photograph
of a completed QDLED c) Electroluminescent performance of the QDLED reported d) The
QDLED is a high efficiency device capable of high brightness. Reprinted by permission
from Chen, Hao, et al. "Quantum dot light emitting devices for photomedical applications."
Journal of the Society for Information Display 25.3 (2017): 177-184.
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Figure 2.16: Photograph and schematic of the QDLED photobiomodulation therapy. [81]
a) Photograph of the red QDLED with 620 nm peak emission b) The QDLED is placed un-
derneath the transparent cell culture wells to perform in-vitro photobiomodulation therapy
c) Schematic of the control experiment with no illumination d) Schematic of the cell lines
receiving photobiomodulation therapy using a QDLED. Reprinted by permission from Chen,
Hao, et al. "Quantum dot light emitting devices for photomedical applications." Journal of
the Society for Information Display 25.3 (2017): 177-184.
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Chapter 3
Integrated Organic LED and Organic
Photodetector on a Highly Flexible
Parylene-C Substrate
3.1 Highly flexible substrate
In order to achieve high levels of flexibility, a polymer based substrate was used. Biocompat-
ible plastic substrates such as poly(ethylene 2,6-naphthalate) and poly(ethyl benzene-1,4-
dicarboxylate), or PEN and PET respectively, are commonly used for flexible displays using
OLEDs. However, the bending radius for these substrates are typically limited to around
5 mm.[82, 2] In order to achieve higher flexibility and conformal attachment, free-standing
parylene-c is used as the substrate and encapsulation. Parylene (poly(p-xylylene)) is a poly-
mer, deposited by chemical vapor deposition, which is often used for barrier coatings and
biocompatible membranes/interfaces.[83] Parylene-c is the variant of the parylene polymer
which has one chlorine group per repeat unit (Figure 3.1). Conformal coatings of parylene-c
are chemically and electrically inert, biocompatible films,[84, 85] ideal for passivating the
devices and protecting them from the environment of the brain.
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Figure 3.1: Parylene-C Structure
3.2 OLED and OPD Structure
The device used in this chapter consists of an OLED and OPD fabricated on a flexible sub-
strate (Figure 3.2).[86] A phosphorescent tris[2-phenylpyridinato-C2,N]iridium(III)-based
(Ir(ppy)3) OLED was used.[39] The higher quantum and electrical efficiency of phospho-
rescent OLEDs over fluorescent OLEDs results in higher light output and longer opera-
tional lifetimes of OLEDs.[40, 43] The structure of the OLED stack is shown in Figure 3.2.
The electron blocking layer (EBL) consists of molybdenum trioxide (MoO3). A layer of
4,4´-bis(N-carbazolyl)-1,1´-biphenyl (CBP) is doped with Ir(ppy)3 to form the hole trans-
port (HTL) and emissive (EML) layer where phosphorescent charge recombination occurs .
Bathocuproine (BCP) forms the electron transport layer (ETL), and a thin layer of lithium
fluoride (LiF) acts as a hole blocking layer (HBL). The photosensitive heterojunction of the
OPD is formed by copper(II) phthalocyanine (CuPc) , a metallic-organic semiconductor of-
ten used in organic photovoltaics, and fullerene (C60).[87, 88] MoO3 forms the EBL followed
by CuPc donor and C60 acceptor layers. BCP forms the ETL with a thin LiF HBL.
The OLED and OPD pixels are 0.5 mm x 0.5 mm in dimension and are spaced apart by
0.8 mm. By applying state-of-the-art commercial fabrication processes for patterning the
OLED and OPD. Smaller pixel sizes and spacing between elements may be achieved for sub-
millimeter imaging resolutions over a large surface area. The OLED is a bottom-emitting
device with a semi-transparent gold anode on the bottom of the stack. The OPD similarly















Figure 3.2: Schematic of the OLED and OPD structure. A photograph showing the layout
of the OLED and OPD on the ORIS device is shown.
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3.3 Fabrication
First, glass slides are cleaned by sonication baths in dilute soap (Micro-90) solution, acetone,
and isopropyl alcohol (IPA) in that order for 15 minutes each. Next, 2 µm of parylene-c
are deposited via CVD to form the bottom encapsulation and substrate. The substrates are
transferred to a nitrogen filled glovebox and into an evaporator housed within the glovebox.
Then 40 nm gold anodes are deposited via thermal evaporation at a rate of 0.4 Å/s. At
thicknesses below 50 nm, gold forms flexible, semi-transparent electrodes. Since organic
semiconductors are typically sensitive to solvents and high temperatures, the patterning of
electrodes and material stacks are carried out via shadow masking.
The organic layers for the OLED are then thermally evaporated under high vacuum.
MoO3 / CBP:Ir(ppy)3(10%) / BCP / Alq3/ are deposited in that order. After a mask
exchange, the organic layers for the OPD are thermally evaporated adjacent to the OLED
stack. MoO3 / CuPc / C60 / BCP are evaporated are deposited in that order. Finally,
1nm LiF is and 100 nm of aluminum are thermally evaporated to form a hole blocking layer
and cathode for both the OLED and OPD. A layer of copper is evaporated over the areas
where the metal traces are eventually contacted to provide mechanical support and allow
the traces to withstand the contacting process.
After the OLEDs and OPDs have been completed, the devices are transferred immedi-
ately to the parylene coater to receive a top coating of 2 µm parylene-c. Vinyl hard masks
are used to protect the contacts from being insulated by the parylene. After the hard masks
are removed, the electrodes are contacted via hot bar bonding with heat seal connector.
The completed devices are then mechanically exfoliated from the glass carriers and tested.
The entire fabrication process is shown in schematic in Figure 3.3. This device architecture
also allows for the incorporation of more complex substrates and encapsulation layers in-
volving alternating stacks of parylene-c and oxide films, which have been shown to improve
operating lifetimes of OLED devices. [89]
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Figure 3.3: Fabrication of Organic Implantable ORIS Sensor
3.4 Device Performance
The resulting ORIS devices fabricated on free standing parylene membranes are less than
5 µm thick and exhibit high flexibility (Figure 3.4). The thin profile and high flexibility of
the device ensures that it will be able to comfortably be implanted underneath the skull.
Additionally, the thin substrate minimizes cross-talk between the emitter and detector.
Figure 3.4b shows the device bending around a wire with an 80 µm diameter while emitting
green light. The device is also shown operating after being wrinkled (Figure 3.4c) and
exposed to saline solution (Figure 3.4d). The device can also attach to wet surfaces that
have arbitrary geometries without the need for adhesive, as seen in Figure 3.4e.
The Ir(ppy)3 based OLEDs have a peak emission wavelength 540 nm, which overlapss
with an isosbestic point of hemoglobin (Figure 3.5). The OPD used in the device has a
broadband spectral response with an effective range between 450 nm and 700 nm (Figure
3.6). This allows the same OPD to be used for detection at non-isosbestic wavelengths in
addition to the 540 nm isosbestic point, enabling the measurement of other biosignals such
as oxygenation. The OPD is operated in photovoltaic mode (zero electrical bias). Under
these conditions, the OPD has a responsivity over 3.6 A/W (3.7). The ratio of dark current
(no illumination) to photocurrent during exposure to green LED light is over 1500. This
responsivity means the OPD is highly sensitivity to changes in reflectivity necessary for
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Figure 3.4: Flexible ORIS Sensor
performing ORIS measurement.
During the ORIS measurement, the OLEDs are supplied with a constant current between
50 µA and 100 µA. At these current densities, the light emission is on the order of ~100
cd/m2 with voltages on the order of ~8.2 V (Figure 3.8), more than sufficient brightness
for performing the ORIS measurements while attached to the surface of the brain. The
operational lifetime of the OLED is shown in Figure 3.9. The operating lifetime of the
device is dominated by the OLED's performance since the OPD receives zero electrical bias
and thus experiences significantly less electrical stress. To test the lifetime of the OLEDs,
the OLEDs are supplied with a constant current, while the emitted luminance is measured
with a luminance meter (Konica Minolta LS-10). The lifetime of the OLED is defined as
the time it takes for the luminance of the OLED to decay to half its initial value. The test
is carried out both in atmospheric conditions in air and while the devices are immersed in
saline solution, to simulate the wet conditions of the brain. The lifetime of the devices in the
aqueous conditions is over an hour, which is sufficient for performing acute measurements
of seizures and neural activity. While the lifetime is not long enough to perform chronic
measurements of epilepsy, where the patients need to be monitored for days or weeks at a
time, the lifetimes of the device can be improved by introducing encapsulation layers into
the parylene-c substrates[89].
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Figure 3.5: OLED Emission Spectrum . The emission spectrum has a peak emission at 540
nm which overlaps with an isosbestic wavelength for hemoglobin.
Figure 3.6: Normalized Spectral Response of OPD . The 540nm isosbestic wavelength used
in the ORIS measurements is denoted with a dashed line.
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Figure 3.7: OPD Photocurrent Response. The ON/OFF ratio between photocurrent gener-
ated under illumination and the background current under dark conditions is over 1500
Figure 3.8: OLED Electrical Current and Light Output. With a bias voltage of 8.2 V, the
OLED outputs 5.6 µW of light, roughly 100 cd/m2.
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Figure 3.9: OLED Operational Lifetime. The luminance half-life is marked with a dashed
line. The device has a lifetime over an hour when exposed to saline solution.
3.5 In Vivo Measurement of Neural Activity and Detection
of Seizures
The organic-based ORIS device records in vivo measurement of cerebral blood volume (CBV)
on the surface of a rat's brain. The rat is anaesthetized and the brain is surgically exposed
for attachment of the ORIS device. A needle electrode measuring the local field potential
(LFP) as a reference signal for neural activity is implanted near the ORIS device's site of
attachment (Figure 3.10). The OLED is then powered to produce light input into the brain
tissue, while the photocurrent generated in the OPD by the reflected light is recorded by an
analog-to-digital converter. The photocurrent is amplified using a current amplifier whose
output is recorded by an analog to digital converter.
Baseline variations of CBV are measured, including hemodynamic changes due to the
heartbeat, respiration, and slow sinusoidal harmonic oscillations in the brain of the animal
(Figure 3.11). A fast Fourier transform (FFT) shows the heartbeat and respiration with
frequencies of 5.7 Hz and 1 Hz respectively. After baseline measurements are recorded,
4-aminopyridine (4AP) is locally injected into the brain via the needle electrode, inducing
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epileptic-like seizures. Figure 3.12 shows the ORIS device's ability to detect seizures, which
are highlighted by . The presence of a seizure is confirmed by the exaggerated oscillations in
the LFP. At the onset of seizure, the drastic increase in neural activity triggers a hemody-
namic response which results in a large flow of blood to the regions of the brain affected by
the seizure. The increase in CBV means more of the light input from the OLED is absorbed
and a decrease in the reflected OI signal (around 10% drop in the OI signal is observed,
during each seizure). As the neural activity returns to the baseline, the CBV in the area re-
turns to normal, and the OI signal increases back to the baseline. This behavior is observed
for every seizure that occurs during the recording session, demonstrating the reliability of
this technique as an alternative to ECoG detection of seizures.
Figure 3.10: Photo of the organic ORIS device attached to the surface of the brain. The
OLED and OPD elements are circled in yellow, while the needle electrode is marked by a
green box.
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Figure 3.11: Baseline variations in the CBV of the animal's brain recorded by the organic
ORIS device. The optical intrinsic (OI) signal captured by the organic ORIS device is
shown at the top with a fast Fourier transform (FFT) of the OI shown directly below it.
Isolated signals of SSHO, respiration, and heartbeat are extracted from the OI signal by
notch filtering and plotted.
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Figure 3.12: In vivo seizure detection using the organic ORIS device. The two plots at the
top show the LFP and OI signal recorded simultaneously during a sequence of seizures. The
duration of seizures is shaded in pink. A more detailed view of a single seizure that occurred
in the middle of the sequence is shown below. The processed OI signal was produced by




In this chapter, an organic-based implantable ORIS sensor for in vivo detection of seizures
was discussed. The complete device included OLEDs and OPDs fabricated on a biocom-
patible, free standing parylene-c substrate with a total thickness under 5 µm, including
encapsulation. The flexibility, performance, and seizure detection ability of the device was
discussed, demonstrating the potential for application as a clinical alternative to ECoG




4.1 Bi-directional Emitter/Detector MicroLEDs
The commercial microLEDs used in this work are CREE DA1000 and CREE DA850 LEDs.
The unique feature of these microLEDs are preformed AuSn solder bumps for eutectic die
attach. This allows the microLEDs to be soldered to a substrate or circuit by aligning and
heating the chips without the need to place solder on the bond pads. The DA 1000 LEDs
have dimensions of 1 mm x 1 mm x 335µm . The DA 850 LEDs have dimensions of 850 µm
x 850 µm x 335 µm.
Figure 4.1: Photograph of the microLEDs soldered onto a glass substrate with a Cr/Au
circuit. DA1000 LED (left) is 1 mm in length. DA 850 (right) is 850 µm in length.
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The microLEDs are used as both the emitter and detector for performing ORIS mea-
surements. According to the Mims effect, LEDs are able to convert incoming light of equal
or shorter wavelengths than the emission wavelength into photocurrent, making them effec-
tively low-pass photodiodes.[32, 33] Thus, an array of microLEDs can be multiplexed as both
emitters and detectors. For this work, blue and green microLEDs with emission wavelengths
of 450 nm and 530 nm, respectively, were used. Figure 4.2 shows that the responsivity of
the microLED acting as a photodiode drops significantly at wavelengths above the LED's
emission wavelength. The overall performance of the microLEDs operating in photodiode
mode (zero electrical bias) is presented in Table 4.1.
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450 nm 30 nm 0.022 A/W N/A N/A
Green
microLED
530 nm 28 nm 0.184 A/W 0.0060 A/W 0.0052 A/W
Table 4.1: Responsivity of microLEDs in photodiode mode to 3 different light emissions
used in the ORIS device.
4.2 Device Fabrication
The microLEDs are soldered to a flexible polyimide substrate (Dupont Polyimide Kapton
PV9103). Polyimide is an ideal flexible substrate that can withstand the wet chemical
etching processes for forming the circuitry as well as the thermal processes for reflowing the
microLEDs. The entire fabrication process is shown in Figure 4.3. First Cr/Au circuitry is
thermally evaporated (at pressures on the order of 1 x 10−6 Torr) onto clean polyimide which
is adhered to a glass carrier, and the Au/Cr layers are photolithographically patterned. Flux
is applied to the bond pads and the microLEDs are aligned onto the bond pads. The whole
device is then placed in a IR reflowed oven and thermally reflowed with a peak temperature
of 280 C. After the microLEDs have been reflowed, poly(methyl methacrylate) (PMMA)
photoresist is deposited directly on top of the microLEDs with a pneumatic printer and
annealed at 100 C to harden the PMMA and remove solvents. The PMMA resist serves to
relieve strain on the contacts of the microLEDs during flexing.[63] Heat seal connector is
used to contact the devices by hot bar bonding, and finally, parylene-c is blanket deposited
over the whole device to form a biocompatible encapsulation and interface. The completed





Figure 4.3: Fabrication steps for the microLED ORIS sensor. a) 40 nm Cr and then 150 nm
Au are thermally evaporated onto a 25 µm thick, clean polyimide sheet on a glass carrier. b)
The circuit and bond pads are patterned via photolithography and wet etching. c) Flux is
applied to the bond pads and the microLEDs are placed on the bond pads. The microLEDs
are reflowed in an infrared reflow oven at 280 C. d) PMMA resist is deposited over the
bonded microLEDs using a pneumatic printer. The devices are annealed at 100 C for 90
minutes to harden the PMMA resist and remove the solvent. e) Parylene-C is blanket-coated
over the entire device after contacting the devices hot bar bonding. f) The completed device
is delaminated from the glass carrier.
Figure 4.4: Photographs of the ORIS devices in operation. Left: Completed ORIS device
is shown with a blue microLED operating in emitter mode. Middle: ORIS device flexed
around a rod with 1/2 inch diameter. A green microLED is shown operating at the same
time. Right: MicroLED ORIS device attached to the surface of a rat's brain.
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4.3 In-Vivo Measurement of CBV and Seizure Detection
MicroLED-based ORIS devices with a 850 µm blue microLED emitter and a 1 mm green
microLED detector spaced 1.5 mm apart are attached to the surface of a rat's brain for in vivo
measurement of CBV (Figure 4.4). In the same manner described in the previous chapter,
the rat is anaesthetized and the brain is surgically exposed for attachment of the ORIS
device. A needle electrode measuring the local field potential (LFP) as a reference signal
for neural activity is implanted near the ORIS device's site of attachment. A microLED
in emitter mode is powered, while an adjacent microLED is operated in photodiode mode,
measuring the reflected optical signal.
Baseline variations of cerebral blood volume (CBV) are measured, including hemody-
namic changes due to the heartbeat, respiration, and slow sinusoidal harmonic oscillations
in the brain of the animal (Figure 4.5). The dominant element in the baseline signal is the
heartbeat which is shown having a frequency of 6 Hz.
1 sec
Figure 4.5: Baseline Measurements of CBV by the microLED ORIS device. Left: ORIS
measurement of baseline CBV signals. Variations in the ORIS signal are due to changes in
CBV. Right: FFT of the baseline CBV signals.
After injection of 4AP to induce seizures in the brain, the ORIS device records changes in
the reflected optical signal due to the hemodynamic response to seizures. Seizure detection
using a green microLED in photodiode mode is shown in Figure 4.6. A device with the same









Figure 4.6: In vivo seizure detection using blue-to-green microLED ORIS device. Duration
of seizures are shaded in pink. Seizures are detected with a signal-to-noise ratio greater than
33 dB. SNR is determined by comparing the root mean square amplitude of the baseline









Figure 4.7: In vivo seizure detection using blue-to-blue microLED ORIS device. Duration
of seizures are shaded in pink. High SNR of seizure detection is achieved despite the lower
responsivity of the blue microLEDs.
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At the onset of each seizure, blood rushes to the site of the seizure in response to the
increased neural activity resulting in a dip in the ORIS signal collected by the microLED in
photodiode mode. As the neural activity returns to the baseline, the CBV levels decrease
and the ORIS signal relaxes towards the baseline level. The blue-to-green ORIS device was
able to detect seizures with a signal-to-noise ratio (SNR) greater than 33 dB. The blue-
to-blue device has a similarly high SNR greater than 18 dB, despite the lower responsivity
of the blue microLEDs in photodiode mode since the heartbeat signal presents the largest
source of noise for seizure detection and the amplitude of heartbeat oscillations decreases
with the lower responsivity of the blue microLED detectors.
Another device with 4 microLED elements configured in a linear array is attached to
a rat's brain for detecting localized changes in CBV during seizures. The layout for this
device is shown in Figure 4.8. 2 green microLEDs, PD1 and PD2, operate in photodiode
mode measuring the reflected ORIS signal, while 2 blue microLEDs operate in emitter
mode. PD1, which is closer to the focus of the seizure, observes an increase in CBV and
relaxation back to the baseline with each seizure that occurs. PD2 detects different changes
in CBV at the site of attachment. The recorded CBV changes with varying amplitude
and duration due to dynamic metabolic demands of the brain during seizures of different
severity. This localized hemodynamic response, shown in Figure 4.9, is consistent with earlier
observed measurements of CBV.[29] This demonstration of localization of hemodynamic
changes during seizure events shows the potential of the microLED ORIS device to be
used for large area, high resolution imaging of neural activity. By using a full 2D array
of microLEDs in this device architecture, spatial resolutions on the order of 1 mm x 1
mm are possible. Further, by switching to smaller microLED elements, spatial resolutions
approaching those achieved with CCD cameras ( < 200 µm) may be possible. This kind
of performance at high resolutions would be comparable to advanced ECoG arrays with













Figure 4.8: Layout of the linear array device. The two microLEDs in photodiode mode,
PD1 and PD2, are attached roughly 2 mm and 3.2 mm away from the focus of the seizure











Figure 4.9: Localized measurements of CBV using a linear array of microLEDs. The mi-
croLED detector labeled PD2 is 1.2 mm further away from the focus of the seizure than
PD1. The duration of seizures at the epileptic focus are highlighted in pink. Notch filtering
to remove the out of band signals is used to improve the detection of seizures.
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4.4 MicroLED ORIS Sensor with Quantum Dot Optical Down-
Conversion Coating
In order to select emission wavelengths outside of the discrete wavelengths available for com-
mercial microLEDs, quantum dot (QD) composite coatings are applied to microLEDs via
pneumatic printing. CdS/CdSe/CdS core shell quantum dots are suspended in toluene at
a concentration of 20 mg/mL. The QD:PMMA composite is prepared by mixing an equal
weight of the QD (in toluene) solution with 950 A6 PMMA photoresist (MicroChem). The
mixture is heated at 70 C for 45 minutes while being stirred with a magnetic stir bar to
increase the viscosity. The fabrication of the devices with the QD coatings is identical to
the one described above (Figure 4.3), with the QD:PMMA composite replacing PMMA pho-
toresist. By utilizing the pneumatic printing technique described in Yang et al.,[90] the QD
coatings can be applied to individual microLEDs without affecting adjacent elements, allow-
ing for the use of multiple emission wavelengths using only blue microLEDs. Photographs
of the printing set up and microLEDs with applied QD coatings is shown in Figure 4.10.
Figure 4.11 shows the emission spectra for the microLEDs directly after the QD coatings
have been applied. Some of the blue backlight is emitted out due to both light leaking
through the QD coating and back-reflections from the subsrate, but the QD coatings are able
to perform well as color conversion layers with the addition of a color filter for removing the
blue backlight. . For the amber QD coating, 86.2% of the emitted light is down-converted.
For the red QD coating 95.5% of the emitted light is down-converted. For the green QD
coating 89.5% of the emitted light is down-converted. Conversion percentage is calculated
by comparing the integral of light intensity in the 500 nm to 750 nm range to the integral
of light intensity over the entire spectral range.
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Figure 4.10: Pneumatic printing QD optical down-conversion coatings. Photographs left to
right: pneumatic printing set up, green QD coating being applied to a microLED, microLED
with applied amber QD coating.
























Figure 4.11: Emission spectra for MicroLED coatings without filtering. The blue component
of the emitted light is from microLED backlight that has not been absorbed or has been
back-reflected from the substrate.
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Figure 4.12: Emission spectra of optical QD down-conversion of blue microLED backlight.
Inset: photographs of the microLEDs with QD coatings shown operating. Roscolux gel
filters and polyimide sheets are used to filter any blue emission not absorbed by the QDs.
The emission spectra of QD coatings with the addition of color filtering are shown in
Figure 4.12. Roscolux 4690 and 2003 gel filters are used for the red and amber QD coatings,
while polyimide sheets are used for the green QD coatings to filter out any blue backlight
that is not absorbed by the QDs. Using QD coatings such as the three variants shown in this
work enables the control of emission wavelength within a few nm with a narrow (<50 nm
FWHM) spectrum. The hardened composites also provide a dual function of strain relief
for the contacts. [63]
An implantable ORIS device with a green QD down-conversion is attached to the surface
of a rat's brain for ORIS measurement of seizure events. The green QD coating has a peak
emission wavelength of 555 nm, and an adjacent green microLED records the reflected ORIS
signal. The device is able to detect changes in CBV due to the hemodynamic response of









Figure 4.13: Seizure detection using a microLED ORIS device with green QD down-
conversion coating. Duration of seizures is highlighted in pink. Notch filtering to remove
the out-of-band signals is used to improve the detection of seizures.
The ability to select specific wavelengths for measurement expands the applicability of
the device to other isosbestic points in the hemoglobin absorbance spectrum as well as other
biomedical fields. Various isosbestic wavelengths are preferred for clinical, diagnostic mea-
surement [91] and having the ability to target a desired isosbestic point without having to
drastically alter the device architecture and materials makes the microLED ORIS device
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a versatile choice for clinical and biomedical research applications. Additionally, applica-
tions such as pulse-oximetry which requires simultaneous measurement of non-isosbestic
points and the measurement of fetal hemglobin, which has a different absorbance spec-
trum than adult hemoglobin, may benefit from this device architecture.[92] An implantable
ORIS monitoring device can even be configured to provide optogenetic-triggered inhibition
of seizures.[93]
4.5 Chapter Summary
An ORIS device comprised of bi-directional microLED emitter/detector pairs integrated
on a flexible polyimide substrate are presented. Localization of hemodynamic response
to seizures is reported as well as the use of QD optical down-conversion coatings. The
device presented in this chapter has potential for being a next-generation alternative to





Wearable and implantable sensors have great promise for enabling the next generation of
healthcare diagnostics and treatment methods. Although there has been great excitement
over the benefits of computational analysis in personalized healthcare, improvements in
hardware and sensing applications are necessary for extracting relevant, practical data. This
is especially true for surgeons and researchers studying epilepsy. Improvements over current
clinical methods for neuronal mapping have the potential to drastically improve the success
of surgical treatments that involve resection of brain matter. Implantable sensors performing
ORIS measurements of CBV and other factors in the brain have the potential to provide
an alternative method for high spatiotemporal resolution of neuronal activity in clinical
settings.
The work presented here has advanced the development of an implantable optical sensor
for performing ORIS mapping in the brain. These advances include: the design, fabrication,
and testing of implantable ORIS devices using organic LEDs, organic photodetectors, and
microLEDs on a variety of flexible substrates. The demonstrated organics based devices
like the one described in Chapter 3 may be useful for acute clinical measurements and
applications outside of ORIS measurement which require extreme levels of flexibility and
low device thickness. The demonstration of a flexible microLED-based sensor is a candidate
for long-term, chronic measurments of CBV and neuronal activity, thanks to its high optical
performance and long operational lifetimes. Moreover, the localization of seizure activity
in the brain using an arrayed microLED ORIS sensor is a crucial step in achieving full 2D
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mapping of neuronal activity with an implantable ORIS sensor. Finally, the application of
quantum dots to the flexible microLED sensor has extended the functionality of such devices,
by increasing the effective range of available emission wavelengths produced by commercial
microLEDs.
Much work remains in developing an implantable ORIS system capable of high spa-
tiotemporal, 2D mapping of neuronal activity. In addition to continued advancement of the
hardware, combining the sensors developed in this work with advanced computational and
analysis methods may provide even higher fidelity sensing and open the devices to new appli-
cations. With continued development, an optical pacemaker for the brain may eventually
be achieved. Such a device would couple the continuous monitoring of neuronal activity the
ability to locally administer treatments such as optogenetic-triggered neuronal inhibition,
drug delivery, or electric stimulation. This would mark a true leap in the diagnosis and
treatment of neurological diseases such as epilepsy.
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Colloidal quantum dots are typically synthesized by arrested precipitation,where a surfac-
tant stabilized solution of semiconductor nanoparticles are capped with organic ligands.[? ]
The precipitated nanocrystals are purified by filtration or centrifugation and washed. The
dry QDs are then re-suspended in a compatible solvent for application by solution pro-
cessing in optoelectronic devices. Although the organic ligands provide size tunability and
solubility, they can also lower the photoluminescent yield of the QDs and are vulnerable to
degradation.[94] QDs with an inorganic shell have been shown to improve photoluminescent
yield and stability.[95, 96]
The QDs used in this work (Chapter 4), have a CdS/CdSe/CdS core shell structure (Fig-
ure 5.1), prepared by first forming CdS and then growing CdSe and outer CdS layers.[95]
Zincblende CdS nanocrystals of the appropriate size were synthesized grown using a cad-
mium oleate solution with a sulphur-based precursor solution, as described in work by
Hamachi et al.[97] Without purifying the nanocrystals, the CdSe shell layer is grown us-
ing cadmium oleate and either N,N'-diethyl imidazolidine-2-selenone or N,N'-di tert-butyl
imidazolidine-2-selenone as selenide precursors.[98] The outer CdS shell is grown with slight
modifications[95] at either 240°C or 290°C using cadmium oleate and another sulfide precur-
sor. The nanocrystals are purified by centrifugation and resuspended in anhydrous toluene.
The synthesis process and storage occurs in an airfree glovebox prior to use. The resulting


































Figure 5.2: QD absorption (left) and photoluminescent (right) spectra for 3 different variants
of CdS/CdSe/CdS core shell QDs suspended in toluene.
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